Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of LAIS Grass tablets in grass pollen-induced allergic rhinoconjunctivitis
2011-002174-23Phase 2Completed
- Sponsor
- Lofarma S.p.A.
- Start
- Jun 2011
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of Lais Graminacee in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Lofarma S.p.A. Primary endpoint: Primary efficacy endpoint. Started Jun 2011; status: completed.
02
Drugs
Lais Graminacee
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2011-002174-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002174-23.